PROS1 and leukemia: In leukemia cells, combined treatment of AZD0364 (ERK1/2 inhibitor) and ZSTK474 (PI3K inhibitor) reduced nuclear factor-κB and antioxidant protein levels (Nrf2, HO-1, thioredoxin reductase and the reduced glutathione/oxidized glutathione ratio) [31].